Welcome to our dedicated page for Akebia Therapeut SEC filings (Ticker: AKBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Akebia Therapeutics, Inc. (Nasdaq: AKBA) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering investors structured access to its official communications. As a biopharmaceutical company focused on kidney disease, Akebia uses filings such as Forms 8-K, 10-K, and 10-Q to report material agreements, financial performance, and key clinical and regulatory developments related to products like Vafseo (vadadustat) and Auryxia (ferric citrate), as well as its rare kidney disease pipeline.
Recent 8-K filings illustrate the type of information investors can expect. One filing describes an amendment to Akebia’s License Agreement with MEDICE Arzneimittel Putter GmbH & Co. KG, under which Akebia supplies vadadustat drug substance and Medice has rights to manufacture Vafseo tablets for Europe and certain other countries, with resulting know-how and patent rights owned by Akebia. Other 8-Ks furnish quarterly financial results, highlight business updates such as Vafseo commercialization metrics, and disclose regulatory decisions, including Akebia’s announcement that it does not plan to initiate the VALOR trial and does not expect to pursue a broad label for Vafseo in CKD patients not on dialysis.
Through this page, users can review annual reports on Form 10-K for comprehensive discussions of risk factors, product portfolios, and strategy; quarterly reports on Form 10-Q for interim financial and operational updates; and current reports on Form 8-K for material events. Insider transaction reports on Form 4, when available, provide visibility into equity transactions by directors and officers. Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight material changes, and help readers quickly understand how new disclosures may relate to Akebia’s kidney disease programs and overall business.
Akebia Therapeutics CEO and President John P. Butler reported an open‑market purchase of 69,270 shares of common stock on March 4, 2026 at an average price of $1.25 per share, with individual trades between $1.23 and $1.28. Following this transaction, his directly held stake rose to 3,367,064 shares of common stock. The filing also notes 159,928 shares held indirectly through the Dorothy Butler Revocable Trust November 20, 2007. A footnote explains that this purchase was matchable under Section 16(b) against a prior sale of 341,305 shares at $1.39 on February 2, 2026, and Butler paid $9,664.60 to Akebia, representing the full short‑swing profit.
Akebia Therapeutics is a kidney-focused biopharmaceutical company with two commercial oral drugs and a growing pipeline. Vafseo (vadadustat), the only oral HIF-based treatment for anemia due to chronic kidney disease in U.S. dialysis patients, launched in January 2025 into a roughly $1 billion market and already has prescribing access for about 290,000 dialysis patients.
Auryxia (ferric citrate) treats hyperphosphatemia in dialysis patients and iron deficiency anemia in non‑dialysis CKD, but lost U.S. exclusivity in March 2025, with broader generic competition expected in 2026 that could pressure revenue. Akebia is advancing mid‑stage rare kidney disease programs praliciguat (Phase 2 in FSGS) and AKB‑097 (planned Phase 2 basket in C3G, IgAN and lupus nephritis), plus early HIF candidates AKB‑9090 for cardiac surgery–related acute kidney injury and potential ARDS use, and AKB‑10108 for retinopathy of prematurity. The company highlights significant ongoing losses, the need for additional financing, heavy dependence on Auryxia and Vafseo, and extensive regulatory, clinical, manufacturing and intellectual‑property risks.
Akebia Therapeutics reported higher fourth quarter and full-year 2025 results, driven mainly by Vafseo and Auryxia. Total revenue rose to $57.6 million in Q4 2025 from $46.5 million a year earlier and to $236.2 million for 2025 from $160.2 million in 2024. Vafseo net product revenue reached $45.8 million in its first full year, while Auryxia generated $181.5 million. Net loss narrowed sharply to $5.3 million for 2025 from $69.4 million in 2024, helped by higher sales and lower amortization charges. Cash and cash equivalents increased to $184.8 million at December 31, 2025, from $51.9 million a year earlier, and the company expects current cash and operating cash flow to fund its plan for at least two years. Management anticipates significant Vafseo revenue growth in 2026 but expects Auryxia revenue to decline as generic competition expands, while advancing multiple Phase 2 and Phase 3 trials in rare kidney diseases.
State Street Corporation has disclosed a passive ownership stake in Akebia Therapeutics Inc. common stock on a Schedule 13G. As of 12/31/2025, State Street reported beneficial ownership of 13,687,561 shares, representing 5.2% of Akebia’s outstanding common stock.
State Street reported no sole voting or dispositive power over these shares, but shared voting power over 13,169,907 shares and shared dispositive power over 13,687,561 shares. The filing states the securities were acquired and are held in the ordinary course of business, not to change or influence control of Akebia.
Akebia Therapeutics SVP and Chief Accounting Officer Richard C. Malabre reported two stock sales of Akebia Therapeutics, Inc. common shares. On February 2, 2026, he sold 36,142 shares at $1.39 per share and 13,382 shares at $1.39 per share.
The transactions were executed under a Rule 10b5-1 trading plan adopted on September 8, 2025, and were made automatically by the company to cover tax withholding obligations related to vesting of restricted stock units granted on January 31, 2024 and January 31, 2025. After these transactions, Malabre directly owned 299,390 common shares of Akebia.
Akebia Therapeutics chief commercial officer Nicholas Grund reported sales of company stock. On February 2, 2026, he sold 53,585 shares of Akebia common stock at $1.39 per share, followed by an additional sale of 31,244 shares at the same price.
According to the footnotes, one sale was made under a pre-arranged Rule 10b5-1 trading plan, and other sales were made automatically by Akebia to cover tax withholding tied to the vesting and settlement of restricted stock units granted in January 2024 and January 2025. After these transactions, Grund directly owned 561,750 shares of Akebia common stock.
Akebia Therapeutics SVP and Chief Medical Officer Steven K. Burke reported routine share sales tied to equity compensation and a pre-set plan. On February 2, 2026, he sold 21,582, 25,375, and 20,701 shares of common stock, each at $1.39 per share.
The filing states one sale was made under a Rule 10b5-1 trading plan adopted on November 17, 2023, and the other two were automatic sales by Akebia to cover tax withholding obligations upon vesting of restricted stock units granted in 2023, 2024, and 2025. After these transactions, Burke directly beneficially owned 948,432 shares of Akebia common stock.
Akebia Therapeutics SVP and Chief Legal Officer Carolyn M. Rucci reported multiple automatic stock sales tied to equity compensation. On February 2, 2026, she sold 16,846, 25,382, and 27,544 shares of Akebia common stock at $1.39 per share in separate transactions.
The filing states one sale was made under a Rule 10b5-1 trading plan adopted on September 8, 2025. The other sales were made automatically by Akebia to cover tax withholding obligations upon vesting and settlement of restricted stock units granted on January 31, 2023, January 31, 2024, and January 31, 2025. After these transactions, Rucci directly beneficially owned 588,378 shares of common stock.
Akebia Therapeutics, Inc. executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer, reported a sale of common stock. On February 2, 2026, he sold 34,951 shares at $1.39 per share.
According to the filing, the sale was made automatically by Akebia to cover tax withholding obligations tied to the vesting and settlement of one-third of his restricted stock units granted on January 31, 2025. The transaction was carried out under a Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, he beneficially owns 672,635 shares of Akebia common stock directly.
Akebia Therapeutics CEO and President John P. Butler, who is also a director, reported several transactions in Akebia common stock on February 2, 2026. He sold 46,660, 96,065, 114,891, and 83,689 shares at